ZYUS Life Sciences Corporation (TSXV:ZYUS)

Canada flag Canada · Delayed Price · Currency is CAD
0.7000
+0.0100 (1.45%)
Oct 22, 2025, 12:51 PM EDT
1.45%
Market Cap54.70M
Revenue (ttm)483.00K
Net Income (ttm)-34.04M
Shares Out78.15M
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,500
Average Volume9,700
Open0.7000
Previous Close0.6900
Day's Range0.7000 - 0.7000
52-Week Range0.5500 - 1.0000
Beta0.84
RSI54.49
Earnings DateNov 28, 2025

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada. [Read more]

Sector Healthcare
Founded 2018
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol ZYUS
Full Company Profile

Financial Performance

In 2024, ZYUS Life Sciences's revenue was 481,000, an increase of 37.04% compared to the previous year's 351,000. Losses were -33.81 million, -20.63% less than in 2023.

Financial Statements

News

There is no news available yet.